ALVO OAKTREE ACQUISITION CORP II

Alvotech Submits its Application for Admission of the Company’s Shares to Trading on Nasdaq Iceland Main Market

Alvotech Submits its Application for Admission of the Company’s Shares to Trading on Nasdaq Iceland Main Market

Alvotech S.A. (“Alvotech”) has submitted its application to Nasdaq Iceland for admission of its shares for trading on the Nasdaq Iceland Main Market under the ticker symbol “ALVO”. The application awaits approval from Nasdaq Iceland.

Alvotech’s shares are currently listed on the Nasdaq Stock Market in the U.S. and on the Nasdaq First North Growth Market under the ticker symbol “ALVO”. Alvotech’s shares were admitted to trading in the U.S. on  and in Iceland on .

On 12 August 2022, Alvotech that the Board of Directors had approved a plan to move its share listing to the Nasdaq Main Market in Iceland.

Alvotech Investor Relations and Global Communication

Benedikt Stefansson



EN
30/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OAKTREE ACQUISITION CORP II

 PRESS RELEASE

European Medicines Agency Recommends Marketing Approval of Gobivaz®, A...

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner REYKJAVIK, ICELAND and LONDON, UK (September 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Med...

 PRESS RELEASE

European Medicines Agency Recommends Marketing Approval of Gobivaz®, A...

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the E...

 PRESS RELEASE

Lyfjastofnun Evrópu mælir með leyfi til markaðssetningar á Gobivaz, fy...

Lyfjastofnun Evrópu mælir með leyfi til markaðssetningar á Gobivaz, fyrirhugaðri hliðstæðu Alvotech við líftæknilyfið Simponi (golimumab) Mannalyfjanefnd (CHMP) Lyfjastofnunar Evrópu (EMA) hefur mælt með því að heimila markaðssetningu AVT05, sem er fyrirhuguð hliðstæða líftæknilyfsins Simponi (golimumab), sem þróuð var af Alvotech. Framkvæmdastjórn Evrópusambandsins veitir í kjölfar jákvæðrar umsagnar CHMP leyfi til markaðssetningar á Evrópska efnahagssvæðinu. Var þetta tilkynnt í dag af Alvotech og samstarfsaðila þess um markaðssetningu Gobivaz, Advanz Pharma, alþjóðlegu lyfjafyrirtæki með...

 PRESS RELEASE

Alvotech Announces Marketing Approval in Japan of Three New Biosimilar...

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars REYKJAVIK, ICELAND (September 19, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in Japan, Fuji Pharma Co., Ltd. (“Fuji Pharma”), has received marketing approval for three new biosimilars from the Japanese Ministry of Health, Labor and Welfare. The biosimilars approved for the Japanese market are AVT03, a biosimilar to Ranmark® (denosumab), AVT05, a biosimilar to S...

 PRESS RELEASE

Markaðsleyfi veitt í Japan fyrir þrjár nýjar líftæknilyfjahliðstæður f...

Markaðsleyfi veitt í Japan fyrir þrjár nýjar líftæknilyfjahliðstæður frá Alvotech REYKJAVÍK 19. september 2025 - Alvotech (NASDAQ: ALVO, ALVO-SDB) tilkynnti í dag að japanska heilbrigðis-, atvinnu- og velferðarráðuneytið hafi veitt Fuji Pharma Co. Ltd. („Fuji Pharma“), samstarfsaðila Alvotech í Japan, leyfi til markaðssetningar og sölu á þremur nýjum líftæknilyfjahliðstæðum sem þróaðar voru og eru framleiddar af Alvotech, AVT03, hliðstæðu við Xgeva (denosumab) sem heitir Ranmark í Japan, AVT05, hliðstæðu við Simponi (golimumab) og AVT06, hliðstæðu við Eylea (aflibercept). AVT05 er fyrsta hl...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch